e-SPACE Heart Failure 2022
Published: 19 October 2022
Part 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
Part 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
Part 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
Part 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
Part 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
Part 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
Part 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations Philippe Gabriel Steg, Shelley Zieroth, Milton Packer, Muthiah Vaduganathan, Cecilia Bahit , Subodh Verma
Part 1 | Session 7 Satellite Symposium: SGLT2 inhibition as foundational heart failure therapy: have we changed our practices? (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Andrew JS Coats, Shelley Zieroth, Stefan Anker, Daniela Tomasoni, Clara Saldarriaga
Part 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2) Giuseppe Galati, Altamash Y. Shaikh, Ewa Jankowska, George L Bakris, Stephan Von Haehling, Javed Butler
Part 1 | Session 9 Meet the expert: Best practice recommendations for the management of hyperkalemia (Supported by an educational grant from AstraZeneca) Clara Bonanad Lozano , Aaron Wong
Part 1 | Session 10 Meet the expert: Hyperkalaemia in patients with heart failure – dreadful side effect or manageable condition? (Supported by an unrestricted educational grant from CSL Vifor) Javed Butler, Ileana L Piña
Part 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs Mitja Lainscak, Ambarish Pandey, Faiez Zannad, Justin Ezekowitz, Ileana L Piña, Harriette Van Spall
Part 1 | Session 12 Meet the expert: Sex differences in advanced heart failure Andrew JS Coats, Aditi Nayak
Part 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF Antonio Ceriello, Naveed Sattar, Stefan Anker, Tammy Lyn Kindel, Andrew JS Coats, Jean-Philippe Minart
Part 2 | Session 1 Plenary Session 7: New technologies to manage your patients Vijay Chopra, Rishi Sethi, Friedrich Koehler, Jasper J Brugts, William T Abraham, Leor Perl
Part 2 | Session 2 Meet the expert: Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients (Sponsored by an unrestricted grant from CVRx) Stefan Anker, Marat Fudim
Part 2 | Session 3 Plenary Session 8: New technologies to treat your patients Sajid Ansari, Fadi Jouhra, Marat Fudim, Johann Bauersachs, William T Abraham, Thomas Thum
Part 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines Stefan Anker, Paul A Heidenreich, Antoni Bayés-Genís, Biykem Bozkurt, Gerasimos Filippatos, John GF Cleland
Part 2 | Session 5 Satellite Symposim: Bridging the implementation gap in heart failure across the EF spectrum (Supported by an educational grant from AstraZeneca) John JV McMurray, Biykem Bozkurt, Giuseppe Rosano, Stephen J Greene
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Executive Director of Research
Dr Katherine R Tuttle, is Professor of Medicine in the Nephrology Division and Kidney Research Institute at the University of Washington, US. Executive Director for Research at Providence Inland Northwest Health, and a Co-Principal Investigator for the ITHS. Her major research interests are in the areas of clinical and translational science and precision medicine for diabetic kidney disease, chronic kidney disease, diabetes, and hypertension. Dr Tuttle has led a major patient registry as well as clinical trials in these fields that have delivered breakthrough therapies to prevent kidney failure and cardiovascular events.
Mehmet Birhan Yilmaz
Petar M Seferovic
Dr Sivadasanpillai Harikrishnan is a professor of cardiology at the Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, (an institute of national importance under the government of India) and is
Dr Harikrishnan received his medical training at the Medical Collage Trivabdum at the University of Calicut, Malappuram, India, and went on to specialise in Cardiology at the Sree Chitra Tirunal Institute for Medical Sciences in 1988. He is involved in international research regarding heart failure, and set up the first heart failure registry in India with the support of the Indian Council of Medical Research.
Dr Harikrishnan is an editorial Board member of Cardiac Failure Review and with…
Dr Yuhui Zhang is vice director of the Heart Failure Center and HFCU at Beijing Fuwai hospital, National Center for Cardiovascular Diseases in China.
She is secretary-general of the Chinese Heart Failure Association, the China National Heart Failure Society, the National HF Quality Control, the HF Medical Consortium, the Heart Failure specialist center Project, the China International Heart Failure Congress and of the Heart Failure Forum of China Heart Congress.
Professor of Cardiology
Dr Clara Saldarriaga is an Editorial Board member of Cardiac Failure Review and may be contacted here.
Dr Saldarriaga completed her undergraduate studies in Medicine at the Jesus Maria School in Medellin in 1994 and went on to continue her studies at the Medical School at the University of Antioquia in 2002. She then went on to complete her Internal Medicine Residency at the University of Antioquia in 2008.
Dr Saldarriaga is currently a Professor of Cardiology at Cardiovascular Clinic Santa Maria at the University of Antioquia in Medellín. She is a member of…